Home » Newsletters » BioWorld Science

BioWorld Science

July 1, 1999

View Archived Issues

Melatonin may be useful in treating REM sleep behavior disorder

Gene sequences related to X-linked inhibitor of apoptosis protein discovered

Introgen Therapeutics receives milestone payment from RPR

NCI initiates phase I trials with patient-specific cancer vaccines

InKine files two patent applications relating to thrombospondin receptor

Novel antiinflammatory agent ML-3000 shows excellent gastroduodenal tolerability

Biotec forms distribution alliance with Organon Teknika for TB test

Acellular pertussis vaccine approved in Canada for adults, adolescents

Alza's Doxil approved in U.S. for treatment of refractory ovarian cancer

Valentis moves IL-2 gene therapy to phase II

Gilead seeks approval for adefovir dipivoxil in the U.S.

5-Halo- or nitrate-substituted paclitaxels under study at Bristol-Myers Squibb

Cell adhesion inhibitors designed at Merck & Co.

Coulter, SmithKline Beecham file BLA for Bexxar

CDK4-specific antisense oligodeoxynucleotides for inhibition of tumors

Relief in sight for female patients with IBS: Glaxo Wellcome files NDA for alosetron

Novel tyrphostins with antiproliferative activity via inhibition of PDGF receptor tyrosine kinase

Corvas presents novel peptide aldehydes as thrombin inhibitors

Nippon Kayaku's new agents for micturition disorders

Team from NCI designs resistance-repellent HIV protease inhibitors

New macrolide antibiotics prepared at Taisho

Potent murine CCR2 receptor antagonist presented at World Congress on Inflammation

SJ-3366, a dual inhibitor of HIV reverse transcriptase and viral attachment

9-Benzyladenine PDE4 inhibitors and their effects on cytokine production

FDA approves new formulation of Abbott's Norvir

Novartis improves upon an effective transplant drug

Brazilian investigators design new antiinflammatory/antiplatelet thienopyrazolopyridines

OP-1 Implant filed for approval on two continents for orthopedic indication

New sublingual beta-blocker enters phase IIb trial in angina pectoris

Results of European studies on sirolimus discussed at Oslo congress

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...